Clinical Trial Update: Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Open-label Phase 1 dose-escalation study of 4SC-205, an Eg5 kinesin-spindle inhibitor, in patients with advanced solid tumors and malignant lymphomas; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• 4SC-205 (Eg5 kinesin-spindle inhibitor)

Snippet

Sponsor: 4SC AG | Conditions: Advanced and Incurable Solid Tumors, Malignant Lymphomas | Phase 1 | Status: COMPLETED